Smallpox projects send stocks soaring

The discovery of monkeypox in several countries has led to share price increases at a number of companies with smallpox vaccines or treatments in their portfolios, including Bavarian Nordic.
Photo: Philip Davali/Ekstra Bladet, Philip Davali
Photo: Philip Davali/Ekstra Bladet, Philip Davali
by marketwire, translated by catherine brett

Reports of monkeypox in several European countries have sent Bavarian Nordic’s share price soaring. On Thursday May 19, it had jumped by 30%, and by Friday lunchtime, this had increased by a further 19%.

Already a subscriber?Log in here

Read the whole article

Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

With your free trial you get:

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
Must be at least 8 characters, including three of: Uppercase, lowercase, numbers, symbols
Must contain at least 2 characters
Must contain at least 2 characters

Get full access for you and your coworkers

Start a free company trial today

Share article

Sign up for our newsletter

Stay ahead of development by receiving our newsletter on the latest sector knowledge.

Newsletter terms

Front page now

Further reading